1 asset in Systemic Epstein-Barr Virus-Positive T-Cell Lymphoproliferative Disease Of Childhood

Therapeutic assets addressing Systemic Epstein-Barr Virus-Positive T-Cell Lymphoproliferative Disease Of Childhood, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Immunoglobulin G1, Anti-(Human/Macaca Fascicularis/Macaca Mulatta Killer Cell Lectin-Like Receptor Klrd1) (Human Monoclonal Dr-01 ?1-Chain), Disulfide With Human Monoclonal Dr-01 ?-Chain, Dimer Systemic Epstein-Barr Virus-Positive T-Cell Lymphoproliferative Disease Of Childhood	Dren Bio	P1/2	CCC (48)